Fluoroquinolones and respiratory tract infections: Do they work?

Infectious Diseases in Clinical Practice

Volumn 6, Issue SUPPL. 2, 1997, Pages

  File Jr , Thomas M ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; LEGIONELLA; LOWER RESPIRATORY TRACT INFECTION; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; PNEUMONIA; REVIEW; SINUSITIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 9844254474     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199711002-00006     Document Type: Review

References (77)

1. Hooper DC, Quinolones. In: Mandell GL, Bennett JE, Dolin R. editors. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone; 1995. p. 364-76.
2. Andriole VT. Quinolones. In: Gorbach SL, Bartiett JG, Blacklow NL. editors Infectious diseases. 1st ed. Philadelphia: Saunders; 1992. p. 244-53.
3. Gwaltney JM, Jr Sinusitis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone; 1995. p. 585-90.
4. Ramadan HH. What is the bacteriology of chronic sinusitis in adults? Am J Otolaryngol 1995;16:303-6.
5. Bartlett JG, Mundy LM. Community-acquired pneumonia N Engl J Med 1995;333:1618-24
6. Fass RJ. Outpatient treatment of lower respiratory tract infections. Infect Dis Clin Pract 1994;3(3 Suppl):S138-S144.
7. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987;1: 671-4.
8. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990;69:307-16.
9. Donowitz GR, Mandell GL. Acute pneumonia. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th ed New York: Churchill Livingstone; 1995. p. 619-37.
10. Reynolds HY. Chronic bronchitis and acute infectious exacerbations In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone; 1995. p. 608-12.
11. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease - state of the art. Am Rev Respir Dis 1992;146:1067-83.
12. Hass H, Morris JF, Samson S, et al. Bacterial flora of the respiratory tract in chronic bronchitis. Comparison of transtracheal, fiber-bronchoscopic and oropharyngeal sampling methods. Am Rev Respir Dis 1977;116:41.
13. Chodosh S. Bronchitis and asthma. In: Gorbach SL, Bartlett JG, Blacklow NL, editors. Infectious diseases. 1st ed. Philadelphia: Saunders; 1992. p. 476-85.
14. Paterson I, Petrie GR, Crompton GK, Robertson JR. Chronic bronchitis: is bacteriological examination of sputum necessary? Br Med J 1978;3:537-8.
15. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy in acute exacerbations of chronic bronchitis: a controlled study using tetracycline. Ann Intem Med 1982;97:18-21.
16. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273:957-60.
17. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204
18. Monk JP, Campoli-Richards DM. Ofloxacin: a review of its antibacterial activity, pharmacokinetic properties and clinical use. Drugs 1987;33.346-91.
19. Canton E, Peman J, Jimenez MT, Ramon MS, Gobernado M. In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob Agents Chemother 1992;36:558-65
20. Kaku M, Ishida K, Irifune K, et al. In vitro and in vivo activities, of sparfloxacin against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994;38:738-41.
21. Eliopoulos GM, Eliopoulos CT. Activity in vitro of the quinolones. In: Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents 2nd ed. Washington (DC): American Society for Microbiology: 1993. p. 161-93.
22. Isaacson DM, Fernandez JA, Frosco M, et al. Levofloxacin: a review of its antibacterial activity Recent Res Dev Antimicrob Agents Chemother 1996;1 391-439.
23. Visser MR, Rozenberg-Arska M, Beumer H, Hoepelman IM, Verhoef J. Comparative in vitro antibacterial activity of sparfloxacin, a new quinolone. Antimicrob Agents Chemother 1991,35:858-68.
24. ZAGAM® (sparfloxacin) Prescribing information. Collegeville (PA): Rhône-Poulenc Rorer Pharmaceuticals; 1996.
25. Karabalut N, Drusano GL. Pharmacokinetics of the quinolone antimicrobial agents. In. Hooper DC. Wolfson JS, editors. Quinolone antimicrobial agents. 2nd ed. Washington (DC): American Society for Microbiology: 1993, p. 195-244.
26. Harazin K, Kobayashi H, Tanimoto H, Matsumoto K, Oizumi K. An open randomized comparison of ofloxacin and doxycycline in lower respiratory tract infections. Drugs 1987;34(1 Suppl):S71-S73.
27. Rademaker CMA, Sips AP, Beurner HM, Hoeplman IM, Overbeck BP, Mollers MJ, et al. A double-blind comparison of low-dose ofloxacin and amoxicillin/clavulanic acid in acute exacerbations of chronic bronchitis J Antimicrob Chemother 1990;26(Suppl D):S75-S81.
28. Fujimori I, Kobayashi Y, Obana M, Saito A, Tomizawa M. Comparative clinical study of ofloxacin and cefaclor in bacterial bronchitis. Kansenshogaku Zasshi 1984;58:861.
29. Forsberg P, Mailer R, Nilsson L. Comparative study of oral ofloxacin and erythromycin in the treatment of pneumonia. Rev Infect Dis 1989;11(5 Suppl):S1229-S1230.
30. Boye NP, Gaustad P. Double-blind comparative study of ofloxacin and trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbations of chronic bronchitis and chronic obstructive lung disease. Infection 1991;19(7 Suppl):S388-S390.
31. Stocks JM, Wallace RJJ, Griffith DE, Garcia JG, Kohler RB. Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin. Am J Med 1989;87(6C Suppl):S52-S56.
32. DeSimone C, DiFabio S, Moretti S, Tzantzoglou S, Trinchieri V. Gargiulo M. Open randomized controlled parallel study of ofloxacin vs. trimethoprim-sulfamethoxazole treatment of lower respiratory tract and urinary infections. Chemotherapy 1991;37(1 Suppl):S39-S48.
33. Plouffe JF, Herbert MT, File TM Jr, et al. Ofloxacin vs. standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Antimicrob Agents Chemother 1996;40:1175-9.
34. Sanders WE, Alessi P, Madres AT, McCloskey RV, Iannini P, Bittner MJ. Oral ofloxacin for the treatment of acute bacterial pneumonia. Use of a non-traditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial. Am J Med 1991;91:261-6.
35. Gentry LO, Rodriguez-Gomez G, Kohler RB, Khan FA, Rytel MW. Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. Am Rev Respir Dis 1992; 145:31-5.
36. Grassi C, Grassi GC, Mangiarotti P A multi-center study on clinical efficacy of ofloxacin in lower respiratory tract infections. Drugs 1987:34(1 Suppl).S80-S82
37. Scully BE. Therapy of respiratory tract infections with quinolone antimicrobial agents. In: Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents. 2nd ed. Washington (DC): American Society for Microbiology; 1993 p. 339-62.
38. Sanbe B, Yoshihama H, Veda R, et al. Experimental and clinical studies on DL-8280 in the field of otorhinolaryngology. Chemotherapy (Tokyo) 1984;32(1 Suppl):S1019-S1029.
39. Sugita R, Kawamura Y, Fujimaki Y, Deguchi K. Clinical experience of DL-8280 in otorhinolaryngological infections. Chemotherapy (Tokyo) 1984;32(1 Suppl)-S1013-S1018.
40. Wollschlager CM, Raoff S, Khan F, Guarneri JJ, Labombardi V, Afzal Q. Controlled comparative study of ciprofloxacin vs. ampicillin in the treatment of bacterial respiratory tract infections. Am J Med 1987;82(4A Suppl): S164-S168.
41. Gleadhill IC, Ferguson W, Lowry RC. Efficacy and safety of ciprofloxacin in patients with respiratory infection in comparison with amoxycillin. J Antimicrob Chemother 1986;18(Suppl D):S133-S138.
42. Magnani C, Gregni S, Valli G, Consentini R, Bisseti A. Comparative efficacy of ciprofloxacin and co-trimoxazole in respiratory tract infections. In: Neu HC, Werta H, editors. Proceedings of the 1st International Ciprofloxacin Workshop. Amsterdam. Excerpta Medica; 1985. p. 260-64.
43. Bantz PM, Goote J, Peters-Hartel W, et al. Low-dose ciprofloxacin in respiratory tract infections. A randomized comparison with doxycycline in general practice. Am J Med 1987;82(4A Suppl):S208-S210.
44. Feist H, Vetter N, Drlicek M, Otupal I, Werta H. Comparative study of ciprofloxacin and cephalexin in die treatment of patients with lower respiratory tract infections. In: Neu HC, Werta H, editors. Proceedings of the 1st International Ciprofloxacin Workshop. Amsterdam: Excerpta Medica, 1986. p. 165-267.
45. Schmidt EW, Zimmermann I, Ritzerfeld W, Voss E, Ulmer WT. Controlled prospective study of oral amoxycillin/ clavulanate vs. ciprofloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1989;24 (Suppl B):S185-S193.
46. Chodosh S, Tuck J, Stottmeier KD, Pizzuto D. Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis. A double-blind crossover study. Am J Med 1989,87(5A Suppl):S107-S112.
47. Trenholme GM, Schmitt BA, Spear J, Gvazdinskas LC, Levin S. Randomized study of intravenous/oral ciprofloxacin vs. ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections Am J Med 1989;87(5A Suppl):S116-S118
48. Haddow A, Greene S, Heinz G, Wantuck D. Ciprofloxacin (intravenous/oral) vs. ceftazidime in lower respiratory tract infections. Am J Med 1989:87(5A Suppl):S113-S115.
49. Khan F, Basir R Sequential intravenous-oral administration of ciprofloxacin vs. ceftazidime in serious bacterial respiratory tract infections Chest 1989;96:528-37.
50. Peterson PK, Stein DJ, Guay DR, et al. Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin. Am J Med 1988;85:164-71.
51. Hirata-Dulas CA, Stein DJ, Guay DR, Gruninger RP, Peterson PK. A randomized study of ciprofloxacin vs. ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections. J Am Geriatr Soc 1991;39:979-85.
52. Fass RJ. Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections. Am J Med 1987;82:202-7.
53. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991;324:384-94.
54. Neu HC. Quinolones in perspective. J Antimicrob Chemother 1990;26(Suppl B):S1-S5.
55. Fomberur JP, Barrault S, Koubbi G, et al. Study of the efficacy and safety of ciprofloxacin in the treatment of chronic sinusitis. Chemotherapy 1994;40(1 Suppl):S24-S28.
56. Falser M, Mittermayer J, Weuta H. Antibacterial treatment of otitis and sinusitis with ciprofloxacin and penicillin V - a comparison. Infection 1988;16(1 Suppl):S51-S54
57. Legent F, Bordure P, Beauvillain C, Berche P. A double-blind comparison of ciprofloxacin and amoxycillin/cla-vulanic acid in the treatment of chronic sinusitis Chemotherapy 1994;40(1 Suppl):S8-S15.
58. Grassi C, Albera C, Pozzi E. Lomefloxacin vs. amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study. Am J Med 1992;92(4A Suppl):S103-S107.
59. Gotfried MH, Ellison WT Safety and efficacy of lomefloxacin vs. cefaclor in the treatment of acute exacerbations of chronic bronchitis. Am J Med 1992;92(4A Suppl): S108-S113.
60. Rizk E. The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone. Am J Med 1992;92(4A Suppl):S130-S135.
61. McCue JD, Payne KJ, Rizk E. A comprehensive review of clinical and in vitro studies of lomefloxacin. Drugs Today 1995;30:535-56.
62. Bensch G. Treatment of community-acquired pneumonia with sparfloxacin and erythromycin [abstract LM12]. In: Proceedings and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996; New Orleans (LA). Washington (DC): American Society for Microbiology, 1996:282.
63. Donowitz G. Treatment of community-acquired pneumonia with sparfloxacin and cefaclor [abstract LM10]. In: Proceedings and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996, New Orleans (LA). Washington (DC): American Society for Microbiology. 1996:282.
64. Plouffe JF, Franklin County Pneumonia Study Group. Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1996;25:43-5.
65. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of iv/oral levofloxacin vs. ceftriaxone/cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72
66. Fogarty C, Sullivan J, Chattman MS, Williams RR, Kojak C, Rubin A. Once-a-day levofloxacin in the treatment of severe and mild-to-moderate community-acquired pneumonia in adults [abstract]. In: Proceedings and abstracts of the 34th Annual Meeting of the Infectious Diseases Society of America; September 18-20, 1996; New Orleans (LA). Washington (DC): American Society for Microbiology, 1996.
67. Habib MP, Gentry LO, Rodriguez-Gomez G, et al. A multicenter, randomized study comparing the efficacy and safety of oral levofloxacin vs cefaclor in the treatment of acute bacterial exacerbations of chronic bronchitis [abstract LM2] In: Proceedings and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 15-18, 1996; New Orleans (LA). Washington (DC): American Society for Microbiology, 1996.
68. DeAbate CA, Russell M, McElvaine P, et al. Safety and efficacy of oral levofloxacin vs. cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1997;42:206-13.
69. Adelglass J, DeAbate CA, McElvaine P, Fowler CL. A comparison of levofloxacin and amoxicillin/clavulanate for the treatment of acute bacterial sinusitis in adults [abstract 290]. Clin Infect Dis 1996;23:913.
70. Sydnor TA, Kopp EJ, Anthony KE, LoCoco JM, Kim S-S, Fowler CL. An open-label assessment of the activity of levofloxacin for the treatment of acute community-acquired bacterial sinusitis in adults. Ann Allergy Asthma Immunol. In press 1997.
71. Thys JP. Quinolones in the treatment of bronchopulmonary infections Rev Infect Dis 1988;10(1 Suppl):S212-S217.
72. Hoogkamp-Korstanje JAA, Klein SJ. Ciprofloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1986;18:407-13.
73. Davies BI, Maesen FPV, Baur C. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur J Clin Microbiol 1986;5:226-31.
74. Sanders WE. Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections. Rev Infect Dis 1988;10:528-43.
75. Lee BL, Padula AM, Kimbrough RC, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991;325:520-1.
76. Gordon JJ, Kauffman CA. Superinfection with Streptococcus pneumonias during therapy with ciprofloxacin. Am J Med 1990;89:383-4.
77. Azoulay-Dupuis E, Bedos JP, Vallee E, Hardy DJ, Swanson RN, Pocidalo JJ. Antipneumococcal activity of ciprofloxacin, ofloxacin and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J Infect Dis 1991;163:319-24.